Danish life science tools company Fida Biosystems ApS has secured a €5m extension to its Series A round, the total size of which remains undisclosed. Swedish Fåhraeus Startup and Growth Fund (FSG) joins as a new lead investor, alongside existing backer EIFO. The funding will accelerate adoption of Fida’s platform and prepare the company for a future Series B round amid strong revenue and instrument sales growth.
FIDA technology
At the heart of Fida’s offering is Flow-Induced Dispersion Analysis (FIDA), a first-principles, in-solution method for characterising biomolecules and nanoparticles. Unlike traditional techniques, FIDA requires no surface immobilisation or pre-defined models. Instead, it uses laminar flow and Taylor dispersion in a microcapillary to deliver precise, quantitative insights into molecular behaviour in complex matrices such as plasma, serum or cell lysates.
A fluorescently labelled indicator molecule and its interaction partners flow through the microcapillary. Radial diffusion is monitored by sensitive fluorescence detection, and data are analysed using physical equations, including the Stokes–Einstein relationship. This yields the absolute hydrodynamic radius (Rh), revealing size, conformational changes, oligomeric state and interaction dynamics in one readout.
Applications
Fida’s immobilisation-free, in-solution approach allows measurement of binding affinity, complex formation, aggregation and sample integrity without surface artefacts. It performs reliably in challenging or viscous samples and consumes minimal material. The latest Fida Neo instrument adds in-solution kinetic measurements, enabling determination of association (k-on) and dissociation (k-off) rates. This provides deeper insight into drug–target interactions for early candidate selection and optimisation.
Industry validation
The platform has seen rapid adoption across pharmaceutical, biotech and academic labs, with over 100 instruments sold and revenues doubling in the past year. Collaborations with established analytical providers highlight FIDA’s value as a complementary technique to methods such as surface plasmon resonance, especially for difficult targets. In mid-December, Cytiva and Fida Biosystems agreed to collaborate in protein research. The agreement combines Cytiva’s Biacore surface plasmon resonance (SPR) systems with Fidabio’s in-solution flow-induced dispersion analysis (FIDA) technology.
Investor confidence
FSG’s investment reflects its focus on Scandinavian technology-driven life sciences, while EIFO’s continued support underlines long-term confidence in Fida’s mission. With the Series A extension in place, the company is positioned to scale commercially and advance innovation at the interface of biophysics and drug discover
Pharmahungary Group
adobe stock photos - deemerwha
Tetraneuron SL - Álvaro García